SE446940B - MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS - Google Patents
MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITSInfo
- Publication number
- SE446940B SE446940B SE8300847A SE8300847A SE446940B SE 446940 B SE446940 B SE 446940B SE 8300847 A SE8300847 A SE 8300847A SE 8300847 A SE8300847 A SE 8300847A SE 446940 B SE446940 B SE 446940B
- Authority
- SE
- Sweden
- Prior art keywords
- agent
- fruits
- berries
- residue
- pulp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
446 940 2 DETALJERAÜ BESKRIVNING AV UPPFINNINGEN Patogena bakterier avger exotoxiner som framkallar illamående, kräkningar, diarréer och yrsel. Uppfinningen baserar sig på insikten att exotoxinerna är proteiner med både anjonisk- och katjonisk karaktär och kan därför genom jonbyte absorberas av makromolekylärt material, såsom cellulosa, som innehåller anjoniska karboxylgrupper, och polymera antocyaniner, som är katjoniska genom oxoniumjon eller karboniumjon i resonans med varandra. Genom att det uppfinningsenliga medlet som är avsett för oral administrering innehåller cellulosa kommer exotoxinerna att absorberas på cellulosan och, , då medlet jämväl innehåller antocyaniner, på de poly- mera antocyaninerna och därigenom hindras exotoxinerna från att gå in i organismen och orsaka sjukdomstillstånd i denna. DETAILED DESCRIPTION OF THE INVENTION Pathogenic bacteria emit exotoxins that cause nausea, vomiting, diarrhea and dizziness. The invention is based on the insight that the exotoxins are proteins with both anionic and cationic character and can therefore be absorbed by ion exchange of macromolecular material, such as cellulose, which contains anionic carboxyl groups, and polymeric anthocyanins, which are cationic by oxonium ion or carbonium ion in resonance with each other. Because the inventive agent intended for oral administration contains cellulose, the exotoxins will be absorbed on the cellulose and, when the agent also contains anthocyanins, on the polymeric anthocyanins and thereby prevent the exotoxins from entering the organism and causing disease states therein.
I stället medföljer exotoxinerna avföringen ur kroppen. Genom de företrädesvis i medlet ingående organiska syrorna uppnås en hämning av de patogena bakteriernas aktivitet. Organiska syror verkar nämligen toxiskt på framförallt patogena bakterier. Lågt pH tenderar att verka selektivt bakteriostatiskt då för orga- nismen nyttiga bakterier av familjer såsom Lactobacillus och Escherichia gynnas av lågt pH medan patogena såsom Salmonella och Vibrio hämmas. Vissa studier antyder för övrigt att även antocyaniner kan ha viss baktericid verkan; denna är dock för tillfället icke otvetydigt fastlagd.Instead, the exotoxins accompany the feces from the body. Due to the organic acids preferably contained in the agent, an inhibition of the activity of the pathogenic bacteria is achieved. Organic acids have a toxic effect on mainly pathogenic bacteria. Low pH tends to act selectively bacteriostatic as bacteria beneficial to the organism of families such as Lactobacillus and Escherichia benefit from low pH while pathogens such as Salmonella and Vibrio are inhibited. Some studies also suggest that anthocyanins may also have some bactericidal activity; however, this is not currently unambiguously established.
Antocyaniner har fler fysiologiska effekter som är av betydelse för att motverka sjukdomar och skadeverkningar på organismen av exempelvis exotoxiner. Sålunda anger Lietti et al [Arzneím.- Forsch., 26 (5), 829-832 (1976)] kärlskyddande och antiinflam- matorisk verkan av dessa, Crippa et al (tyska offentliggörande- skriften 3 027 933) förbättring av läkning av sår, Pourrat et al [Plantes Médicin. 11, no special, 143-151 (1977)] avsevärda förbättringar i patienternas tillstànd vid arterioskleros, corønarskleros, cirrhøsis, i venerna vid blödningar och vid användning av antikoagulenter, samt Seeger [Ärtzliche Forschung 21 (2), 68-78 (1967)] karcinostatisk verkan. Anto- cyaninerna verkar som vitamin P med dubbelt så stark verkan som 'rutin och stärker väggarna i blodkärlen samt minskar genomblöd- ningen. Den akuta toxiciteten är utomordentligt låg. Pourrat 446 940 anger att den akuta orala toxiciteten inte kunnat bestämmas då LD 0 2 25 g/kg för mus och 2 20 g/kg för råtta, Chim.Anthocyanins have more physiological effects that are important in counteracting diseases and harmful effects on the organism of, for example, exotoxins. Thus, Lietti et al [Arzneím.- Forsch., 26 (5), 829-832 (1976)] state vascular protective and anti-inflammatory effect thereof, Crippa et al (German Publication No. 3,027,933) improving the healing of wounds. , Pourrat et al [Medicinal Plants. 11, no special, 143-151 (1977)] significant improvements in the patients' condition in arteriosclerosis, coronary sclerosis, cirrhosis, in the veins during bleeding and in the use of anticoagulants, and Seeger [Ärtzliche Forschung 21 (2), 68-78 (1967) ] carcinostatic effect. The anthocyanins act as vitamin P with twice as strong an effect as 'routine' and strengthen the walls of the blood vessels and reduce blood flow. The acute toxicity is extremely low. Pourrat 446 940 states that the acute oral toxicity could not be determined as LD 0 2 25 g / kg for mouse and 2 20 g / kg for rat, Chim.
Thérap., 2, 33-38 (1967).Thérap., 2, 33-38 (1967).
Genom att således medlet enligt uppfinningen innehåller cellu- losa och såväl organiska syror som antocyaniner erhåller man ett medel med bakteriostatisk, läkande, antiinflammato- risk, bakterieflorenormaliserande ocheammoxinabsorberande verkan. Betydelsefullt är därvid att medlet är väsentligen fritt från eller innehåller förhållandevis ringa mängd bestånds- delar som utgör näring för mikroorganismer såsom närmare kommer att avhandlas härnedan. Cellulosa är i det närmaste inert gentemot mikroorganismer.Thus, since the agent according to the invention contains cellulose and both organic acids and anthocyanins, an agent with bacteriostatic, healing, anti-inflammatory, bacterial florenormalizing and ammoxin-absorbing action is obtained. It is significant that the agent is substantially free of or contains a relatively small amount of constituents that constitute nutrients for microorganisms, as will be discussed in more detail below. Cellulose is virtually inert to microorganisms.
Cellulosan verkar förutom som absorbent för exotoxinerna som bärare av antocyaninerna och de organiska syrorna genom mage och tarmkanal på ett sådant sätt att verkan erhålles i hela matsmältningsapparaten. Antocyaninerna och de organiska syrorna är alltså upptagna i cellulosan och löses därför kon- tinuerligt ut under transporten genom apparaten. I tolvfinger- tarmen är miljön svagt alkalisk' och därför gynnsam för till- växt av ett flertal patogena mikroorganismer som salmonella och vibrio, av vilka enstaka individer kan ha passerat den starkt sura miljön i magsäcken utan att avdödas. De organiska syrorna i medlet motverkar här tillväxt av patogena mikroorga- nismer. I tunntarm och tjocktarm är miljön åter sur.In addition to being an absorbent of the exotoxins, the cellulose acts as a carrier for the anthocyanins and the organic acids through the stomach and intestinal tract in such a way that action is obtained throughout the digestive system. The anthocyanins and the organic acids are thus absorbed into the cellulose and are therefore continuously released during transport through the apparatus. In the duodenum, the environment is weakly alkaline 'and therefore favorable for the growth of a number of pathogenic microorganisms such as salmonella and vibrio, some of which individuals may have passed the strongly acidic environment in the stomach without being killed. The organic acids in the product here counteract the growth of pathogenic microorganisms. In the small intestine and large intestine, the environment is acidic again.
Enligt uppfinningen förfar man för framställning av medlet så att man från bär eller frukter som naturligen innehåller cellulosa, organiska syror och antocyaniner avlägsnar huvud- delen av fruktköttet och företrädesvis även eventuella kärnor, varefter återstoden utnyttjas såsom eller för beredning av medlet. Uppfinningen baserar sig på insikten att i bär och 44e 940. 4 frukter, sådana som Ribes nigrum L (svarta vinbär), Vaccinium myrtíllus L (blåbär), Vaccinium Vitis-idaéa L (lingon), Sambucus nigra (fläderbär), Vitis vínifera (vindruvor) etc, som innehåller varierande mängder av bland annat organiska syror, pektiner, garvämnen, socker, antocyaniner och cellulosa, finns näringen för mikroorganismerna, nämligen sockret, till övervägande del i fruktköttet. Genom att i enlighet med den uppfinningsenliga anvisningen avskilja huvuddelen av frukt- köttet och för medlet använda återstoden så att alltså medlet kommer att innehålla förhållandevis ringa mängd beståndsdelar som utgör näring för mikroorganismerna erhåller man en över- raskande stor ökning av effekten jämfört med den som uppnås när man låter patienten förtära jämväl fruktköttet. Den för medlet utnyttjade återstoden som väsentligen befriats från fruktköttet kommer sådeles att verka väsentligen bakterio- statiskt. Eventuellt medverkar också pektinerna och garvämnena till medlets gynnsamma verkan på organismen.According to the invention, the preparation is carried out in such a way that the main part of the pulp and preferably also any kernels are removed from berries or fruits which naturally contain cellulose, organic acids and anthocyanins, after which the residue is used as or for preparation of the preparation. The invention is based on the insight that in berries and 44e 940. 4 fruits, such as Ribes nigrum L (black currants), Vaccinium myrtíllus L (blueberries), Vaccinium Vitis-idaéa L (lingonberries), Sambucus nigra (elderberries), Vitis vínifera ( grapes), etc., which contain varying amounts of, among other things, organic acids, pectins, tannins, sugar, anthocyanins and cellulose, the nutrients for the microorganisms, namely sugar, are predominantly present in the pulp. By separating the main part of the fruit flesh and using the remainder for the agent in accordance with the invention, so that the agent will thus contain a relatively small amount of constituents which constitute nutrients for the microorganisms, a surprisingly large increase in the effect is obtained compared with that achieved. when allowing the patient to consume the pulp as well. The residue utilized for the agent which has been substantially freed from the pulp will thus have a substantially bacteriostatic effect. Pectins and tannins may also contribute to the beneficial effect of the product on the organism.
Genom att således utgå från naturligen förekommande bär och frukter öppnas möjligheten till ekonomisk framställning av medlet. Avlägsnandet.av fruktköttet utföres företrädesvis genom att bären eller frukterna pressasnmnzen sil med sådan maskvidd att bärens eller frukternas skal eller ytterdelar kvarhålles f medan huvuddelen av fruktköttet ochléknmmm passerar igenom silens öppningar. Pressningen ger således en rest bestående av bärens ellerfrukternas skal och ytterdelar, i vilka finns vad som åsyftas enligt uppfinningen, nämligen cellulosa, organiska syror och antocyaniner. Återstoden uppgår i allmän- het till ca 40 vikts-% men kan variera mellan 10 och 70 vikts~%.By thus starting from naturally occurring berries and fruits, the possibility of economical production of the agent is opened up. The removal of the pulp is preferably carried out by pressing the berries or fruits through a sieve with such a mesh size that the peel or outer parts of the berries or fruits are retained while the main part of the pulp and body passes through the openings of the sieve. The pressing thus gives a residue consisting of the skins and outer parts of the berries or fruits, in which are contained what is referred to according to the invention, namely cellulose, organic acids and anthocyanins. The remainder generally amounts to about 40% by weight but can vary between 10 and 70% by weight.
Den erhållna presskakan torkas härnäst. Antocyaniner ligger nära andra lätt oxiderbara föreningar såsom askorbinsyra och d-CX tokoferolacetat (Efvitamin) på redox-skalan samt har som andra fenolföreningar tendens att polymerisera vid förhöjd temperatur. Det efter pressningen resulterande materialet som skall användas till medlet bör således torkas vid måttliga temperaturer, nämligen vid en temperatur ej överstigande 110°C.The resulting press cake is then dried. Anthocyanins are close to other easily oxidizable compounds such as ascorbic acid and d-CX tocopherol acetate (Efvitamin) on the redox scale and, like other phenolic compounds, tend to polymerize at elevated temperature. The material resulting from the pressing to be used for the composition should thus be dried at moderate temperatures, namely at a temperature not exceeding 110 ° C.
Torkningstemperaturen ligger företrädesvis mellan 40 och 110°C vid atmosfärstryck. Torkningen bör helst utföras vid en tem- 446 949 5 peratur understigande 90°C i vakuum; temperaturintervallet kan t ex vara 35 ~ 90°C.The drying temperature is preferably between 40 and 110 ° C at atmospheric pressure. The drying should preferably be carried out at a temperature below 90 ° C in vacuo; the temperature range can be, for example, 35 ~ 90 ° C.
Halten antocyaniner varierar mellan olika bär och frukter.The content of anthocyanins varies between different berries and fruits.
Halter över 3 g/kg färska här betraktas såsom höga och åter- finns bland annat hos blåbär och svarta vinbär. Hos blàbär är antocyaninerna ungefär jämt fördelade mellan skal och fruktkött.Concentrations above 3 g / kg fresh here are considered high and are found in blueberries and blackcurrants, among other things. In blueberries, the anthocyanins are approximately evenly distributed between the skin and the flesh.
Hos svarta vinbär är största delen koncentrerad till skalet,_ vilket är en fördel när fruktköttet avskiljes.In blackcurrants, most of it is concentrated in the skin, which is an advantage when the pulp is separated.
Det efter torkningen resulterande materialet kan därefter fin- fördelas genom rivning eller malning. Det rivna materialet kan användas för beredning av soppor medan man av det malda mate- rialet kan pressa tabletter, vilka antingen kan användas för beredning av soppor eller intagas hela.The material resulting after drying can then be comminuted by grating or grinding. The grated material can be used for the preparation of soups, while the ground material can be pressed into tablets, which can either be used for the preparation of soups or ingested whole.
Man kan även förfara så att man fryser bären eller frukterna till ~5 à -50°C, vanligen -20°C, varefter bären bringas att passera ett sáll, t ex ett spaltsáll, nätsåll eller hålsàll, där revor och andra växtdelar som huvudsakligen inte tillhör bäret eller frukten avskiljs. Bären eller frukterna tinas sedan och pressas i en sil med sådan maskvidd att fruktkött och kärnor passerar igenom. Presskakan rives och torkas var- efter förfares som ovan beskrivits.It is also possible to freeze the berries or fruits to ~ 5 to -50 ° C, usually -20 ° C, after which the berries are passed through a sieve, for example a slotted sieve, net sieve or hole sieve, where tears and other plant parts such as mainly does not belong to the berry or the fruit is separated. The berries or fruits are then thawed and pressed into a sieve with such a mesh size that the flesh and seeds pass through. The press cake is torn and dried, after which the procedure is as described above.
En dos av det färdiga medlet kan uppgå till 2-10 g men kan vara såväl större som mindre.A dose of the finished agent can amount to 2-10 g but can be both larger and smaller.
Vid framställning av medlet med utgångspunkt från bär eller frukter genom avlägsnande av fruktköttet blir halten antocya- niner minst 10 mg/g medel och i allmänhet ca 25 mg/g medel, dvs 2,5 %. I tidigare nämnda skrift av Crippa et al anges för en salva för yttre bruk 1 % antocyaniner.In the preparation of the agent starting from berries or fruits by removing the pulp, the content of anthocyanins is at least 10 mg / g agent and generally about 25 mg / g agent, ie 2.5%. The aforementioned publication by Crippa et al states for an ointment for external use 1% anthocyanins.
Verkan av det genom avlägsnande av fruktköttet från bär eller frukter framställda medlet kan förstärkas genom att öka halten organiska syror eller antocyaniner eller bådadera genom till- sättning till det färdiga medlet. Antocyaniner kan utvinnas ur bär, exempelvis svarta vinbär, eller frukter enligt kända metoder såsom jonbyte enligt den franska patentskriften 2 299 385. 446 940 6 Genom sin höga halt av antocyaniner bör det uppfinningsen- liga medlet förutom vid akuta magsjukdomar och diarréer också kunna insättas vid andra sjukdomstillstånd i magen, såsom colon irritable, enterit, colit, enterocolit och ulcer.The effect of the agent prepared by removing the pulp from berries or fruits can be enhanced by increasing the content of organic acids or anthocyanins or both by adding to the finished agent. Anthocyanins can be extracted from berries, for example black currants, or fruits according to known methods such as ion exchange according to French patent specification 2,299,385. 446 940 6 Due to their high content of anthocyanins, the inventive agent should be able to be used in addition to acute gastric diseases and diarrhea in other diseases of the stomach, such as irritable bowel syndrome, enteritis, colitis, enterocolitis and ulcers.
Det föredrages att till medlet tillsätts natriumsulfit som motverkar nedbrytning av antocyaninerna. Natriumsulfittill- satsen uppgår företrädesvis till högst 5 vikts-% av medlets torrsubstans.It is preferred that sodium sulfite be added to the agent which counteracts the degradation of the anthocyanins. The sodium sulphite additive preferably amounts to a maximum of 5% by weight of the dry matter of the agent.
EXEMPLIFIERING AV UPPFINNINGEN Exempel 1 ïïkg bär av Ribes nigrum L pressas i en sil med maskvidd 2,5 mm varvid fruktkött och kärnor passerar genom silen. Här- vid erhålles 410 g presskaka, som innehåller dels skalen av bären och dels ett tunt skikt av fruktkött närmast skalet med tillsammans 19 % torrhalt. Presskakan torkas vid 90°C till 94 % torrhalt, varvid 83 g torkat material erhålles. Det torkade materialet males därefter och sållas på ett nät med maskvidd 2 mm. Av det sàllade materialet tillverkas tabletter à 600 mg. 1_g av den malda produkten ger vid uppslamning i 100 ml destil- lerat vatten pH 3,2 vid 37°C. Elektrometrisk titrering av upp- slamningen med 0,1 M natriumhydroxidlösning qarentitrerkurva med utseende enligt bifogat diagram, varvid syrainnehàllet vid titrering till några olika pH ger motsvarande mmol HCl enligt följande tabell. pH HCl, mmol/g 4,0 0,5 5,0 '- 1,1 6,0 1,6 7,0 1,9 Halten organiska syror i medlet motsvarar ca 20 % citronsyra.EXAMPLE OF THE INVENTION Example 1 The berries of Ribes nigrum L are pressed into a 2.5 mm mesh sieve with pulp and seeds passing through the sieve. This gives 410 g of press cake, which contains both the skins of the berries and a thin layer of pulp closest to the skin with a total dry matter content of 19%. The press cake is dried at 90 ° C to 94% dry matter, whereby 83 g of dried material are obtained. The dried material is then ground and sieved on a 2 mm mesh. 600 mg tablets are made from the sold material. 1 g of the ground product, when slurried in 100 ml of distilled water, gives a pH of 3.2 at 37 ° C. Electrometric titration of the slurry with a 0,1 M sodium hydroxide solution charantitre curve with the appearance according to the attached diagram, the acid content when titrated to a few different pH giving the corresponding mmol HCl according to the following table. pH HCl, mmol / g 4.0 0.5 5.0 '- 1.1 6.0 1.6 7.0 1.9 The content of organic acids in the product corresponds to about 20% citric acid.
Exempel 2 1 kgbärznrvaccinium Vitis-idaéa L fryses till -20°C. De frysta bären passerar ett nätsáll med 3 mm maskvidd där mindre partiklar avskiljs. Bären tinas och pressas därefter i en sil med 2 mm maskvidd varvid kärnor och fruktkött avskiljs. Härvid erhålles 416 940 -n l 450 g presskaka med 24 % torrhalt. Den torkas vid 95°C till 93 % torrhalt varvid 116 g torkat material erhålles. Detta behandlas som i föregående exempel.Example 2 1 kg berry vaccine Vitis-ideaa L is frozen at -20 ° C. The frozen berries pass through a mesh sole with a 3 mm mesh width where smaller particles are separated. The berries are thawed and then pressed in a sieve with a 2 mm mesh width, whereby seeds and pulp are separated. 416,940 l of 450 g of press cake with 24% dry content are obtained. It is dried at 95 ° C to 93% dry matter to give 116 g of dried material. This is treated as in the previous example.
Exempel 3 ' I presskakan enligt exempel 1 inblandas 3 vikt-% natriumsulfit.Example 3 '3% by weight of sodium sulphite is mixed into the press cake according to Example 1.
Presskakan torkas vid 90°C till 94 % torrhalt som i exemplet 1 varefter även i övrigt förfares enligt nämnda exempel.a Exempel 4 I presskakan enligt exempel 1 inblandas 5 vikt-% citronsyra och 5 vikt-% mjölksyra samt 1 vikt-% antocyaniner. Presskakan torkas vid 90°C till 94 % torrhalt som i exemplet 1 varefter i övrigt förfares enligt nämnda exempel.The press cake is dried at 90 ° C to 94% dry content as in Example 1, after which the procedure is also carried out according to said example. A Example 4 The press cake according to Example 1 mixes 5% by weight of citric acid and 5% by weight of lactic acid and 1% by weight of anthocyanins. The press cake is dried at 90 ° C to 94% dry content as in Example 1, after which the process is otherwise carried out according to the said example.
Claims (10)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8300847A SE446940B (en) | 1983-02-16 | 1983-02-16 | MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS |
DE1984900900 DE137811T1 (en) | 1983-02-16 | 1984-02-08 | COMPOSITION FOR ELIMINATING DISEASES IN THE DIGESTIVE SYSTEM. |
EP84900900A EP0137811B1 (en) | 1983-02-16 | 1984-02-08 | A preparation for suppressing states of illness in the digestive system |
AT84900900T ATE34299T1 (en) | 1983-02-16 | 1984-02-08 | COMPOSITION TO ELIMINATE DISEASES IN THE DIGESTIVE SYSTEM. |
JP59500931A JPS60500536A (en) | 1983-02-16 | 1984-02-08 | Preparations for suppressing disease states in the digestive system |
DE8484900900T DE3471254D1 (en) | 1983-02-16 | 1984-02-08 | A preparation for suppressing states of illness in the digestive system |
PCT/SE1984/000039 WO1984003216A1 (en) | 1983-02-16 | 1984-02-08 | A preparation for suppressing states of illness in the digestive system |
AU25722/84A AU2572284A (en) | 1983-02-16 | 1984-02-08 | Medel for bekampande av sjukdomstillstand i matsmaltnings- apparaten |
US06/858,783 US4857327A (en) | 1983-02-16 | 1986-05-02 | Method for suppressing states of illness in the digestive system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8300847A SE446940B (en) | 1983-02-16 | 1983-02-16 | MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8300847D0 SE8300847D0 (en) | 1983-02-16 |
SE8300847L SE8300847L (en) | 1984-08-17 |
SE446940B true SE446940B (en) | 1986-10-20 |
Family
ID=20350062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8300847A SE446940B (en) | 1983-02-16 | 1983-02-16 | MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS |
Country Status (6)
Country | Link |
---|---|
US (1) | US4857327A (en) |
EP (1) | EP0137811B1 (en) |
JP (1) | JPS60500536A (en) |
DE (1) | DE3471254D1 (en) |
SE (1) | SE446940B (en) |
WO (1) | WO1984003216A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1231725B (en) * | 1989-08-11 | 1991-12-21 | Inverni Della Beffa Spa | PROCEDURE FOR THE PREPARATION OF HIGH-CONTENT EXTRACTS IN ANTOCYANOSIDES. |
US5645994A (en) * | 1990-07-05 | 1997-07-08 | University Of Utah Research Foundation | Method and compositions for identification of species in a sample using type II topoisomerase sequences |
US5525341A (en) * | 1992-10-09 | 1996-06-11 | Jlb, Inc. | Partially purified cranberry anti-adhesion activity |
US5646178A (en) * | 1992-10-09 | 1997-07-08 | Jlb, Inc. | Cranberry extract and biologically active compounds derived therefrom |
US5650432A (en) * | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5474774A (en) * | 1994-03-25 | 1995-12-12 | Jlb, Inc. | Adhesion inhibiting composition |
US5614501A (en) * | 1994-07-21 | 1997-03-25 | The University Of Montana | Compositions and methods for animal husbandry and for treating gastrointestinal disorders |
US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
WO1997029762A1 (en) * | 1996-02-14 | 1997-08-21 | The Procter & Gamble Company | Urogenital and intestinal compositions |
AU4310697A (en) * | 1996-09-20 | 1998-04-14 | Howard Foundation, The | Method of producing polyphenol-containing compositions |
US6238673B1 (en) | 1996-09-20 | 2001-05-29 | The Howard Foundation | Method of producing high flavonol content polyphenol compositions |
US6569446B1 (en) | 1996-09-20 | 2003-05-27 | The Howard Foundation | Solubilization of flavonols |
CA2269078C (en) | 1996-10-16 | 2012-01-24 | Shaman Pharmaceuticals, Inc. | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
PT1014969E (en) * | 1997-09-09 | 2009-02-17 | Univ Rutgers | Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces |
FR2775686B1 (en) * | 1998-03-09 | 2006-07-28 | Pascal Commenil | INDUSTRIAL AND COMMERCIAL EXPLOITATION OF CUTICULAR LIPIDS IN THE BAY OF GRAPE IN PHARMACOLOGY AND COSMETOLOGY |
JP3437458B2 (en) * | 1998-09-10 | 2003-08-18 | キユーピー株式会社 | Liquid filling method and device for double bag and half-folding device for bag used in the device |
FR2789269B1 (en) * | 1999-02-09 | 2001-06-15 | Ferlux | DIETETIC COMPOSITION BASED ON RED FRUIT EXTRACT (S), MANUFACTURING METHOD AND USE OF SAID COMPOSITION |
US6548076B2 (en) * | 1999-08-17 | 2003-04-15 | Shanbrom Technologies, Llc | Antimicrobial lees |
US6210681B1 (en) * | 1999-09-07 | 2001-04-03 | Jlb, Inc. | Plant proanthocyanidin extracts |
US6960360B2 (en) * | 2000-08-31 | 2005-11-01 | Phenolics, Llc | Efficient method for producing compositions enriched in total phenols |
US7306815B2 (en) * | 2000-08-31 | 2007-12-11 | Phenolics, Llc | Compositions enriched in phenolic compounds and methods for producing the same |
ES2266251T3 (en) * | 2000-08-31 | 2007-03-01 | Phenolics, Llc | EFFECTIVE METHOD FOR PRODUCING ENRICHED COMPOSITIONS WITH ANTOCIANINS. |
FR2814950B1 (en) * | 2000-10-05 | 2003-08-08 | Oreal | USE OF AT LEAST ONE EXTRACT OF AT LEAST ONE PLANT FROM THE ERICACEAE FAMILY, IN COMPOSITIONS FOR TREATING SKIN SIGNS OF AGING |
US7022368B2 (en) * | 2001-06-26 | 2006-04-04 | Ocean Spray Cranberries, Inc. | Process for producing sugars and acids-rich juice and phytochemical-rich juice |
US6733813B2 (en) * | 2001-08-02 | 2004-05-11 | Ocean Spray Cranberries, Inc. | Process for producing acids-enriched juice and acids-reduced juice |
GB0127031D0 (en) * | 2001-11-09 | 2002-01-02 | Medpalett Pharmaceuticals As | Process |
GB0127032D0 (en) | 2001-11-09 | 2002-01-02 | Medpalett Pharmaceuticals As | Product |
US8337914B2 (en) * | 2002-02-27 | 2012-12-25 | Access Business Group International Llc | Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation |
US20060073220A1 (en) * | 2004-07-08 | 2006-04-06 | Daugherty F J | Cinnamon extract enriched for polyphenols and methods of preparing same |
JP2006232765A (en) * | 2005-02-28 | 2006-09-07 | Yakult Honsha Co Ltd | Prophylactic and therapeutic agent for colitis |
RS52678B (en) * | 2006-05-01 | 2013-06-28 | Napo Pharmaceuticals Inc. | Method for treatment of constipation-predominant irritable bowel syndrome |
EP2061327B1 (en) * | 2006-05-01 | 2016-10-05 | Napo Pharmaceuticals, Inc. | Compositions for treating or preventing inflammatory bowel disease |
US20070254050A1 (en) | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
FI122664B (en) * | 2009-03-11 | 2012-05-15 | Teknologian Tutkimuskeskus Vtt | Fractionation of nature's raw products and separation of nutrients from them |
FI20105710A0 (en) * | 2010-06-18 | 2010-06-18 | Pirjo Paernaenen | Preparation for balancing the oral microbial flora |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2461499A1 (en) * | 1979-07-23 | 1981-02-06 | Inverni Della Beffa Spa | Topical compsns. with cicatrising activity - contg. bilberry vaccinium myrtillus extract with high anthocyanoside content |
-
1983
- 1983-02-16 SE SE8300847A patent/SE446940B/en not_active IP Right Cessation
-
1984
- 1984-02-08 JP JP59500931A patent/JPS60500536A/en active Pending
- 1984-02-08 DE DE8484900900T patent/DE3471254D1/en not_active Expired
- 1984-02-08 WO PCT/SE1984/000039 patent/WO1984003216A1/en active IP Right Grant
- 1984-02-08 EP EP84900900A patent/EP0137811B1/en not_active Expired
-
1986
- 1986-05-02 US US06/858,783 patent/US4857327A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPS60500536A (en) | 1985-04-18 |
EP0137811B1 (en) | 1988-05-18 |
SE8300847D0 (en) | 1983-02-16 |
SE8300847L (en) | 1984-08-17 |
EP0137811A1 (en) | 1985-04-24 |
DE3471254D1 (en) | 1988-06-23 |
US4857327A (en) | 1989-08-15 |
WO1984003216A1 (en) | 1984-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE446940B (en) | MEASURES FOR FIGHTING DISEASE CONDITIONS IN THE FOOD MELTER CONTAINING SHALL OR OUTSIDE OF BEERS OR FRUITS | |
KR101424125B1 (en) | Composition for treating inflammatory disease comprising Tenebrio molitor larvae | |
KR20200012969A (en) | Animal feed supplements | |
WO2007003068A1 (en) | Feed additive, its preparation method and application | |
KR20210122439A (en) | Pet Oral composition comprising Seaweed extracts and the Product comprising the same | |
WO2017119797A1 (en) | Growth supplement and nutraceutical composition for improving production efficiency of agricultural and livestock products | |
KR102035261B1 (en) | A composition of feed additives | |
JP2003146898A (en) | Hyperlipemia-improving agent | |
KR102086166B1 (en) | Antimicrobial composition comprising the extracts of rambutan peel | |
CN104719914B (en) | A kind of composition for improving gastrointestinal function and preparation method thereof | |
JP2006232781A (en) | Hypoglycemic composition comprising substance derived from bark of genus acacia | |
EP1864658A1 (en) | Agent for alleviating vascular insufficiency | |
JP2003146899A (en) | Skin-improving agent | |
CN114903128B (en) | Crayfish compound feed and preparation method thereof | |
JP2003063974A (en) | Antioxidant, nitrogen monooxide-production inhibitor, antiulcer drug and food containing the drug component | |
KR102407619B1 (en) | Composition for improving cat hairball discharge | |
KR102372943B1 (en) | Pharmaceutical composition comprising the extract of puparium of black soldier fly as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
Laboni et al. | Biological investigations of different leaf extracts of Litsea liyuyingi (Family-Lauraceae) | |
KR102277059B1 (en) | Pharmaceutical composition comprising the extract of black soldier fly as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
CN113015432B (en) | Compositions comprising sulfated galactose and embodiments thereof | |
JPH01172333A (en) | Preventive and remedy for swine infectious diseases of streptococcus hemolyticus | |
JP2006219376A (en) | Urease inhibitor | |
KR20130103989A (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of cudrania tricuspidata as a main component | |
JP6141841B2 (en) | Crustacean feed | |
JP2006022082A (en) | Lipid metabolism improver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAL | Patent in force |
Ref document number: 8300847-4 Format of ref document f/p: F |
|
NUG | Patent has lapsed |
Ref document number: 8300847-4 Format of ref document f/p: F |